RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 Patients with mCRC Benefit from Active Maintenance Therapy
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 9
OP 10
DO 10.1177/155989771436004
UL http://mdc.sagepub.com/content/14/36/9.abstract
AB The optimal duration of treatment with fluoropyrimidines (FPs), oxaliplatin (OX), and bevacizumab (BEV) for patients with metastatic colorectal cancer (mCRC) is not known. This article presents results from the phase 3 study Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC) [AIO KRK 0207; NCT00973609]. This trial investigated maintenance chemotherapy with FPs+BEV, BEV alone, or no treatment following a 24-week first-line induction with FPs, OX, and BEV for patients with mCRC.